A protein therapeutic modality founded on molecular regulation.
about
In vitro recombination of non-homologous genes can result in gene fusions that confer a switching phenotype to cellsProtein switch engineering by domain insertion.Modular extracellular sensor architecture for engineering mammalian cell-based devices.Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.Rational design of a fusion protein to exhibit disulfide-mediated logic gate behavior.Modular protein switches derived from antibody mimetic proteins.Development of a cancer-marker activated enzymatic switch from the herpes simplex virus thymidine kinase.Transposon for protein engineeringConstruction of Protein Switches by Domain Insertion and Directed Evolution.Design of protein switches based on an ensemble model of allosteryUbiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencingProtein engineering: a new frontier for biological therapeutics.Engineering cell-based therapies to interface robustly with host physiology.Synthetic Protein Switches: Theoretical and Experimental Considerations.Non-allosteric enzyme switches possess larger effector-induced changes in thermodynamic stability than their non-switch analogs.The interplay between effector binding and allostery in an engineered protein switch.Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage.Enzymatic protein switches built from paralogous input domains.Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
P2860
Q28742847-A1FB13C8-08ED-4B29-A9F0-36305B859EC0Q33753116-B1974230-78DA-4A7C-A0F2-48414634B6ECQ34167797-18B11202-4606-401C-AD5E-E1D892C13D78Q35451950-BF835C88-DEB0-471C-821C-C7FB4D5CFF9BQ35541987-4DBC906A-BDB5-4154-A1C4-473264BA8963Q35861468-04263AC1-0A96-4C93-8441-76275892E705Q36227090-A73B7A1C-CB77-4C33-8D55-FEF9D270A987Q36250279-B1DAD1AB-8B0B-417F-A1BC-A25D6459CD71Q36308146-D3F72934-391A-4DFF-8825-BEFDC876C607Q36438734-62110211-A5DD-474F-868E-04925BFAEA79Q37635847-3E3C88E4-2EFE-4CC1-9177-73681EFDCCD0Q38286271-0155696D-B3ED-4E2E-BE70-4837DA8A5629Q38856242-F6C7F1EB-6869-43E7-A01B-C95BC9A4F17AQ38907834-0BEC1A87-FCA5-4026-B14C-90FC6C931C80Q39365378-CC9685E2-4496-4C95-9EA2-01AB674DBC2BQ39703543-6415CC16-6802-411B-8DC2-4D000B7B3F07Q40262447-DEA2C368-1EBD-4558-B266-368C8101197EQ40438592-7D87AD1C-8C27-4C58-B908-BA032454B172Q42770604-91E122A0-B311-4284-A24C-9B06087250A1
P2860
A protein therapeutic modality founded on molecular regulation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A protein therapeutic modality founded on molecular regulation.
@ast
A protein therapeutic modality founded on molecular regulation.
@en
type
label
A protein therapeutic modality founded on molecular regulation.
@ast
A protein therapeutic modality founded on molecular regulation.
@en
prefLabel
A protein therapeutic modality founded on molecular regulation.
@ast
A protein therapeutic modality founded on molecular regulation.
@en
P2093
P2860
P356
P1476
A protein therapeutic modality founded on molecular regulation
@en
P2093
Chapman M Wright
James R Eshleman
R Clay Wright
P2860
P304
16206-16211
P356
10.1073/PNAS.1102803108
P407
P577
2011-09-19T00:00:00Z